Clinical Trials Browser

Phase 1 × Neoplasms × TAS-119 × Clear all

NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Phase 1 Terminated

Epilepsy, Neoplasms